The Global Dilated Cardiomyopathy (DCM) Therapeutics Market is poised for robust growth, projected to increase from USD 1.1 billion in 2023 to USD 1.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period. The increasing burden of heart failure globally, advances in genetic testing, and expanding access to targeted therapies are major forces driving...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek